You say "particularly in moderately-differentiated tumors" -- I have a few questions.
1. Why did you specifically point out "moderately-differentiated?" I ask because my wife has a tumor classified as poorly-differentiated. I'm wondering if the middle ground is unique/harder to diagnose in some way.
2. Would something like this come into play during the initial biopsy or after the tumor is removed? I ask because she has a mastectomy next week. I kind of assumed the nature of the cancer was already figured out with the estrogen+ and her2/neu tests. We never really received a "score" - just a breakdown of the good and the bad characteristics and the suggested treatment plan post surgery - which includes both anti-estrogen drugs AND herceptin.
3. Does it make sense, at this point, to try to get her into Stanford for this C-Path test?
1. Why did you specifically point out "moderately-differentiated?" I ask because my wife has a tumor classified as poorly-differentiated. I'm wondering if the middle ground is unique/harder to diagnose in some way.
2. Would something like this come into play during the initial biopsy or after the tumor is removed? I ask because she has a mastectomy next week. I kind of assumed the nature of the cancer was already figured out with the estrogen+ and her2/neu tests. We never really received a "score" - just a breakdown of the good and the bad characteristics and the suggested treatment plan post surgery - which includes both anti-estrogen drugs AND herceptin.
3. Does it make sense, at this point, to try to get her into Stanford for this C-Path test?
Any input is appreciated.